aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize heart failure treatment, CardioKinetix, Inc. specializes in developing transcatheter implantable devices. The company's core vision is to enhance cardiac function by isolating non-functional muscle segments from functional ones, thereby decreasing ventricular volume and increasing ejection fraction. Their primary product offerings focus on innovative solutions for heart failure patients, aiming to improve overall cardiac performance and patient outcomes within the United States market.
CardioKinetix has garnered attention from notable investors and industry leaders in the medical device sector. The company's pioneering approach has led to significant advancements in heart failure treatment, positioning it as a key player in the field. Through its innovative devices, CardioKinetix has made a substantial impact on improving the quality of life for heart failure patients, demonstrating the potential for transformative healthcare solutions.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Medical Devices
Technology
Biotech
Tags
Hardware, Software
Model Types
Recurring
Revenue Type(s)
Enterprise, Healthtech
Customer Type(s)
United States
When was Cardiokinetix founded?
Cardiokinetix was founded in 2003.
Where is Cardiokinetix's headquarters located?
Cardiokinetix's headquarters is located in Newark, NJ, US.
How many employees does Cardiokinetix have?
Cardiokinetix has 33 employees as of Feb 5, 2024.
How much has Cardiokinetix raised to-date?
As of July 05, 2023, Cardiokinetix has raised a total of $112.5M (USD) since Nov 29, 2016.
Add Comparison
Total Raised to Date
$112.5M
USD
Last Update Nov 29, 2016
Total Employees Over Time
33
As of Feb 2024
Cardiokinetix Address
Newark,
New Jersey
07108
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts